RRM1表达与吉西他滨治疗晚期NSCLC疗效关系_Meta分析.pdf

MedJChinPLA,Vol.37,No.2,February1,2012135

RRM1表达与吉西他滨治疗晚期NSCLC疗效关系:Meta分析

张艳，苏欣，施毅

[摘要]目的对晚期非小细胞肺癌(NSCLC)患者核糖核苷还原酶调节因子1(RRM1)表达水平与吉西他滨化疗疗
效的相关性进行Meta分析。方法通过计算机检索中国知网(CNKI)数据库、万方数据库、PubMed、EMBASE和ASCO
数据库，纳入文献为以中英文发表的全文。收集比较不同RRM1表达水平(高表达/阳性与低表达/阴性)的晚期NSCLC
患者对接受含吉西他滨化疗方案的反应率的文章。采用Cochrane协作网RevMan5.0软件进行分析。结果最终纳入11
项研究，共515例患者。235例为RRM1高表达/阳性患者，合并有效率为17.9%，280例RRM1低表达/阴性患者，合并有
效率为44.3%。异质性检验结果显示各研究不存在统计学异质性(χ2＝10.50，P＝0.40，I2=5%)。采用固定效应模型对文
献进行定量综合分析，合并OR值为3.70，95%可信区间为2.43~5.63，Z=6.11，P<0.00001。结论在晚期NSCLC患者
中，RRM1低表达/阴性者接受吉西他滨化疗的疗效优于RRM1高表达/阳性者。
[关键词]RRM1；非小细胞肺癌；吉西他滨；化疗；Meta分析
[中图分类号]R734.2
[文献标志码]A
[文章编号]0577-7402(2012)02-0135-06

RelationshipbetweenRRM1expressionandtherapeuticeffectsofgemcitabineforadvancednon-
smallcelllungcarcinoma(NSCLC):ameta-analysis
ZHANGYan1,2,SUXin2,SHIYi2*
1ClinicalCollegeofMedicalSchoolofNanjingUniversity,Nanjing210002,China
2DepartmentofRespiratoryMedicine,NanjingGeneralHospitalofNanjingMilitaryCommand,Nanjing210002,China
*Correspondingauthor:E-mail:[e-mail]
[Abstract]ObjectiveThepresentstudypresentsametaanalysisonthecorrelationbetweentheexpressionof
ribonucleosidereductaseregulatoryfactor1(RRM1)andthetherapeuticeffectsofgemcitabineforadvancednon-smallcelllung
cancer(NSCLC).MethodsChineseandEnglishpublicationswereretrievedfromtheCNKI,WANFANG,PubMed,EMBASE,
andASCOdatabasewithanelectroniccomputertocomparetheresponserateoftheadvancedNSCLCpatientswithdifferent
RRM1expressionlevel(highexpression/positiveandlowexpression/negative)togemcitabinechemotherapy.TheCochrane
Collaboration'sRevMan5.0softwarewasadoptedfortheanalysis.ResultsElevenstudies,withatotalof515patients,were
identified.Thenumberofpatientswithhigh/positiveRRM1proteinexpressionwas235,andtheamalgamatedeffectiveratewas
17.9%.Thenumberofpatientswithlow/negativeRRM1proteinexpressionwas280,andtheamalgamatedeffectiveratewas
44.3%.Heterogeneitytestshowednostatisticalheterogeneityamongstudies(χ2=10.50,P=0.40,I2=5%).Thefixedeffectmodelwas
adoptedforacomprehensivequantitativeana